Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Teva announces U.S. FDA approval of three-times-a-week COPAXONE® (glatiramer acetate injection) 40mg/mL
Episode 12 with Professor Gavin Giovannoni on the potential for finding a cure for MS.
Novartis drug Gilenya® shows long-term efficacy and safety according to new data from extension of phase III head-to-head study
Episode 18 with Dr. Samuel Ludwin on new approaches to remyelination therapies.
“Veterinary Medicines” page
Effects of fumaric acids on cuprizone induced central nervous system de- and remyelination in the mouse.
Optical coherence tomography should be part of the routine monitoring of patients with multiple sclerosis: Yes.
Second International Porto Congress of Multiple Sclerosis
Masitinib mesylate application for conditional approval
Meta-analysis of adverse events in recent randomized clinical trials for dimethil fumarate, glatiramer acetate and teriflunomide for the treatment of relapsing forms of multiple sclerosis.
Place of birth, age of immigration, and disability in Hispanics with multiple sclerosis.
Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression.
NYSCF Webinar Series: Multiple Sclerosis and the Promise of Stem Cell Research
The Fourth International Conference on Regulatory T Cells and TH Subsets and Clinical Applications in Human Disease
US and EU regulatory authorities accept oral BG-12 marketing applications for review
Narrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosis.
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination.
Dimethyl fumarate inhibits dendritic cell maturation via nuclear factor kcyB (NF-kcyB) and Extracellular Signal-regulated kinase 1 and 2 (ERK1/2) and Mitogen Stress activated kinase 1 (MSK1) signaling.
American Academy of Neurology Annual Meeting
Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination.
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Therapeutic effects of systemic administration of chaperone αB-crystallin associated with binding proinflammatory plasma proteins.
Keystone Symposium: Viral Immunity
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
Extracellular Cues Influencing Oligodendrocyte Differentiation and (Re)myelination.

Pages